Skip to main content

Advertisement

Table 2 Percentages of EBV specific CTLs in 19 patients at + 30, + 60, and + 90 days after haplo-HSCT and in healthy controls

From: Immune reconstitution of HLA-A*0201/BMLF1- and HLA-A*1101/LMP2-specific Epstein Barr virus cytotoxic T lymphocytes within 90 days after haploidentical hematopoietic stem cell transplantation

Groups Patients/healthy controls (NO.) Percentages at + 30 days Percentages at + 60 days Percentages at + 90 days
HLA-A*0201 group     
  P1 0.1982 2.9100 1.0950
  P2 0.8337 1.9200 1.3644
  P3 0.7296 3.0000 1.0119
  P4 0.3252 3.1700 1.4483
  P5 0.0179 1.9000 1.1990
  P6 1.0790 4.2400
  P7 0.5619 0.6900
  P8 0.2727 0.5300
  P9 0.9600 0.5500
  P10 0.8924
  H1 2.1000   
  H2 0.6200   
  H3 1.5900   
  H4 5.7900   
  H5 1.7700   
  H6 0.3000   
  H7 2.8800   
  H8 1.4700   
  H9 3.4800   
HLA-A*1101 group     
  P1 2.4667 0.0672
  P2 0.3413 0.5073 0.4926
  P3 0.1585 0.3339 0.3434
  P4 1.2534 1.5635 1.0086
  P5 1.0931 2.8223 1.1053
  P6 0.2601 0.5272
  P7 0.6569 0.7229 0.4940
  P8 0.5787 1.0769
  P9 0.1537 0.8800 1.8715
  H1 3.5392   
  H2 0.7454   
  H3 2.1402   
  H4 3.5406   
  H5 2.0589   
  H6 2.7509   
  H7 6.1721   
  H8 0.6712   
  H9 2.7146   
  H10 2.6164   
  H11 0.7193   
  H12 1.4663   
  H13 0.9191   
  H14 6.6107   
  H15 3.5822   
  H16 3.5711   
  H17 2.2981   
  H18 2.6966   
  H19 2.8326   
  1. Abbreviations: P patient, H healthy controls. The percentages of EBV specific CTLs of healthy controls were detected at only one-time point during our study